Showing results (21-30 of 54) with videos related to
Sort By:
Pageof 6
Journal for Immunotherapy of Cancer|February 29, 2024
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapyAllison Betof Warner, Omid Hamid, Krishna Komanduri, et al.Journal of the American Academy of Dermatology|March 21, 2021
Dermatologic infections in cancer patients treated with checkpoint inhibitorsMytrang H Do, Dulce M Barrios, Gregory S Phillips, et al.Pigment Cell & Melanoma Research|April 24, 2023
Diversity, equity, and inclusion in the melanoma research communityMarie E Portuallo, David Y Lu, Gretchen M Alicea, et al.Pigment Cell & Melanoma Research|April 11, 2023
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1Kimberly Loo, Hannah L Kalvin, Katherine S Panageas, et al.Frontiers in Oncology|July 3, 2023
Metformin is associated with improved clinical outcomes in patients with melanoma: a retrospective, multi-institutional studyRyan C Augustin, Ziyu Huang, Fei Ding, et al.Journal for Immunotherapy of Cancer|February 11, 2021
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockadeJason Beattie, Hira Rizvi, Paige Fuentes, et al.Neuro-Oncology Advances|January 7, 2022
Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasisN Ari Wijetunga, Adrienne Boire, Robert J Young, et al.The Oncologist|February 6, 2023
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant ImmunotherapyThomas M Atkinson, Jennifer L Hay, Soo Young Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2020
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 BlockadeAllison Betof Warner, Jessica S Palmer, Alexander N Shoushtari, et al.JCI Insight|October 22, 2021
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitnessDaniel Hirschhorn, Allison Betof Warner, Rachana Maniyar, et al.Pageof 6